Marshall Wace LLP Acquires New Holdings in OptimizeRx Co. (NASDAQ:OPRX)

Marshall Wace LLP bought a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 134,446 shares of the company's stock, valued at approximately $653,000. Marshall Wace LLP owned 0.73% of OptimizeRx at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Whetstone Capital Advisors LLC purchased a new position in OptimizeRx in the 4th quarter valued at about $6,563,000. Royce & Associates LP purchased a new position in OptimizeRx in the fourth quarter valued at about $5,198,000. Kennedy Capital Management LLC grew its stake in OptimizeRx by 57.8% during the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock valued at $2,887,000 after purchasing an additional 217,676 shares in the last quarter. Geode Capital Management LLC increased its holdings in OptimizeRx by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock worth $1,948,000 after purchasing an additional 4,821 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in OptimizeRx during the 4th quarter worth approximately $673,000. Hedge funds and other institutional investors own 76.47% of the company's stock.

Analyst Upgrades and Downgrades

OPRX has been the subject of a number of recent analyst reports. JMP Securities reissued a "market outperform" rating and set a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. Royal Bank of Canada reissued a "sector perform" rating and set a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Finally, B. Riley raised shares of OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, OptimizeRx currently has an average rating of "Moderate Buy" and an average target price of $9.06.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded down $0.42 during trading hours on Monday, reaching $9.63. The company's stock had a trading volume of 239,049 shares, compared to its average volume of 268,140. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx Co. has a one year low of $3.78 and a one year high of $14.13. The company's 50 day simple moving average is $7.69 and its 200 day simple moving average is $6.18. The stock has a market cap of $178.09 million, a P/E ratio of -7.24 and a beta of 1.28.

Insiders Place Their Bets

In related news, Director James Paul Lang purchased 321,408 shares of the company's stock in a transaction dated Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the transaction, the director now owns 389,452 shares of the company's stock, valued at $2,959,835.20. This trade represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.